ArticleBiomimetics (Basel, Switzerland)2024
Enhanced Multi-Strategy Slime Mould Algorithm for Global Optimization Problems.
Article in Biomimetics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In order to further improve performance of the Slime Mould Algorithm, the Enhanced Multi-Strategy Slime Mould Algorithm (EMSMA) is proposed in this paper. There are three main modifications to SMA. Firstly, a leader covariance learning strategy is proposed to replace the anisotropic search operator in SMA to ensure that the agents can evolve in a better direction during the optimization process. Secondly, the best agent is further modified with an improved non-monopoly search mechanism to boost the algorithm's exploitation and exploration capabilities. Finally, a random differential restart mechanism is developed to assist SMA in escaping from local optimality and increasing population diversity when it is stalled. The impacts of three strategies are discussed, and the performance of EMSMA is evaluated on the CEC2017 suite and CEC2022 test suite. The numerical and statistical results show that EMSMA has excellent performance on both test suites and is superior to the SMA variants such as DTSMA, ISMA, AOSMA, LSMA, ESMA, and MSMA in terms of convergence accuracy, convergence speed, and stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.